FDA’s Wood­cock weighs in on role of NIH in drug de­vel­op­ment

The FDA Cen­ter for Drug Eval­u­a­tion and Re­search (CDER) di­rec­tor Janet Wood­cock said Wednes­day that while the NIH has been in­stru­men­tal to drug dis­cov­ery and de­vel­op­ment, she does not think the NIH or aca­d­e­mics should be in the busi­ness of de­vel­op­ing new phar­ma­ceu­ti­cals.

The com­ments came as part of the first day of a two-day meet­ing at the Na­tion­al Acad­e­mies of Sci­ences, En­gi­neer­ing and Med­i­cine in Wash­ing­ton, DC, on the role of the NIH in drug de­vel­op­ment in­no­va­tion and the im­pact on pa­tient ac­cess.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER